K2 Principal Fund’s Apexigen, Inc. WarrantApexigen, Inc. Warrant APGNW Stock Holding History

K2 Principal Fund’s Portfolio APGNW Stock Details APGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-127,682	Closed	-$51K	–	409
2021 Q4	$51K	Hold	127,682	–	–	﹤0.01%	353
2021 Q3	$84K	Buy	+127,682	New	+$123K	0.01%	289

Other funds holding APGNW

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

K2 Principal Fund's APGNW Position: Q1 2022 in Review

K2 Principal Fund sold out of Apexigen, Inc. WarrantApexigen, Inc. Warrant (APGNW) in Q1 2022, closing a stake of 127,682 shares — an estimated $51K sold.

K2 Principal Fund first reported a position in APGNW in Q3 2021 and held it in 2 quarters. The position peaked at $84K in Q3 2021. 12 funds tracked by Wall St. Rank hold APGNW as of Q1 2022.

K2 Principal Fund reported no remaining Apexigen, Inc. WarrantApexigen, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
K2 Principal Fund sold 127,682 Apexigen, Inc. WarrantApexigen, Inc. Warrant shares in Q1 2022, an estimated $51K.
K2 Principal Fund first reported a position in Apexigen, Inc. WarrantApexigen, Inc. Warrant in Q3 2021 and held it in 2 quarters.
K2 Principal Fund's Apexigen, Inc. WarrantApexigen, Inc. Warrant position peaked at $84K in Q3 2021.
12 funds tracked by Wall St. Rank held Apexigen, Inc. WarrantApexigen, Inc. Warrant as of Q1 2022.

Based on K2 Principal Fund's 13F filing for Q1 2022, filed 16 May 2022.